The study of human embryonic stem cells (hESCs) and Induced Pluripotent Stem Cells (iPSC) and its differentiation into specific lineages provides an extraordinary opportunity to study the cellular / molecular mechanisms regulating pluripotency and differentiation. It also offers a potentially unlimited source of numerous cell types for drug screening and cell-based therapies. The Pluripotent Stem Cell Shared Resource Facility has been established to facilitate the transfer of this technology to the Mount Sinai community and other institutions. The objectives of this facility are:
- To provide undifferentiated PSCs, mouse embryonic fibroblasts (MEFs) and/or hematopoietic, cardiac and endoderm progenitors. For more information please visit Getting Started
- To train faculty, postdoctoral fellows and students in the maintenance and the differentiation of pluripotent stem cells. For more information please visit Services
- To provide tested media / reagents necessary for the maintenance as well as the differentiation of pluripotent stem cells at discounted prices. For more information please visit Supply Center
- To karyotype and bank hESC and iPSC stocks. For more information please visit Core Stem Cell Stock
- To generate gene targeted hESC lines (in collaboration with the mouse gene targeting facility). For more information please visit Services
- To assist PIs with pilot hESC projects. For more information please visit Services
- To assist PIs with the development of novel induced pluripotent stem (iPS) cell lines from human patients as well as their differentiation. For more information please visit Services
Induced Pluripotent Stem (iPS) Cells
Recent developments in the field have demonstrated the ability to reprogram adult human cells to an ES cell-like state using only 3 or 4 defined genes. This allows the derivation of patient-specific hiPS cell lines without the major ethical barriers associated with transfer of adult cell nuclei into oocytes. Therefore, a part of the core will be dedicated to assist investigators with the development of novel iPS cell lines and their differentiation.
PLEASE REMEMBER – For funding purposes, it is important to acknowledge the Pluripotent Stem Cell Shared Resource Facility in all publications that include data derived from the facility.